Observational studyAntimicrobial agents and chemotherapy2021
Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.
Observational study in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Research trends and emerging topics in antifungal therapeutic drug monitoring: a bibliometric analysis with implications for clinical pharmacy practice.International journal of clinical pharmacy · 2026Review
- Can Fluconazole Be Used to Treat Non-Resistant Candida (Candidozyma) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model.The Journal of infectious diseases · 2026Article
- Antimicrobial pharmacokinetics in pediatric patients on kidney replacement therapy: a comprehensive narrative review.Pediatric nephrology (Berlin, Germany) · 2026Review
- Population Pharmacokinetic Modeling of Intravenous Fluconazole to Inform eGFR-Based Dosing: A Simulation Study Demonstrating Superiority over Standard Regimens.Pharmaceutics · 2026Article
- Fluconazole Dosing for the Prevention ofPharmaceutics · 2025Article
- Optimizing fluconazole dosing in acute renal failure patients undergoing continuous renal replacement therapy: A population pharmacokinetic/pharmacodynamic study.Frontiers in pharmacology · 2025Article
- The Application of the Design of Experiments and Artificial Neural Networks in the Development of a Fast and Straightforward HPLC-UV Method for Fluconazole Determination in Hemato-Oncologic Pediatric Patients and Its Adaptation to Therapeutic Drug Monitoring.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations forAntimicrobial agents and chemotherapy · 2024Article
- Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations forAntimicrobial agents and chemotherapy · 2024Article
- Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.Antibiotics (Basel, Switzerland) · 2024Article
- UPLC-MS/MS method for fluconazole determination in plasma and its application in Mexican patients with candidaemia.Bioanalysis · 2024Article
- Evaluation of Systemic Antifungal Use in a Latin American General Care Hospital: A Retrospective Study.Pharmacy (Basel, Switzerland) · 2023Article
- The Influence of Extracorporeal Membrane Oxygenation on Antibiotic Pharmacokinetics.Antibiotics (Basel, Switzerland) · 2023Review
- The Effect of Dihydromyricetin on the Pharmacokinetics of Fluconazole in Sprague-Dawley Rat Plasma, Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.Drug design, development and therapy · 2023Article
- Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.Antimicrobial agents and chemotherapy · 2022Article
- Article
- Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients.Microorganisms · 2021Article
- Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?Antimicrobial agents and chemotherapy · 2021Article
- Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?"Antimicrobial agents and chemotherapy · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of fluconazole is related to the area under the plasma concentration-time curve (AUC) over the MIC of the microorganism. Physiological changes in critically ill patients may affect the exposure of fluconazole, and therefore dosing adjustments might be needed. The aim of this study was to evaluate variability in fluconazole drug concentration in intensive care unit (ICU) patients and to develop a pharmacokinetic model to support personalized fluconazole dosing. A prospective observational pharmacokinetic study was performed in critically ill patients receiving fluconazole either as prophylaxis or as treatment. The association between fluconazole exposure and patient variables was studied. Pharmacokinetic modeling was performed with a nonparametric adaptive grid (NPAG) algorithm using R package Pmetrics. Data from 33 patients were available for pharmacokinetic analysis. Patients on dialysis and solid organ transplant patients had a significantly lower exposure to fluconazole. The population was best described with a one-compartment model, where the mean volume of distribution was 51.52 liters (standard deviation [SD], 19.81) and the mean clearance was 0.767 liters/h (SD, 0.46). Creatinine clearance was tested as a potential covariate in the model, but was not included in the final population model. A significant positive correlation was found between the fluconazole exposure (AUC) and the trough concentration (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.